Hikal Limited (NSE:HIKAL)
India · Delayed Price · Currency is INR | Market Cap | 43.53B |
| Revenue (ttm) | 18.60B |
| Net Income (ttm) | 908.00M |
| Shares Out | n/a |
| EPS (ttm) | 7.36 |
| PE Ratio | 47.94 |
| Forward PE | 31.27 |
| Dividend | 1.20 (0.35%) |
| Ex-Dividend Date | Feb 7, 2025 |
| Volume | 205,014 |
| Average Volume | 247,875 |
| Open | 353.00 |
| Previous Close | 352.05 |
| Day's Range | 342.15 - 353.80 |
| 52-Week Range | 309.15 - 464.75 |
| Beta | 0.63 |
| RSI | 46.16 |
| Earnings Date | Aug 5, 2025 |
About Hikal
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India, the United States, Canada, Europe, South East Asia, and internationally. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredients (APIs). Its Crop Protection segment manufactures pesticides and herbicides, wh... [Read more]
Financial Performance
In 2024, Hikal's revenue was 18.60 billion, an increase of 4.21% compared to the previous year's 17.85 billion. Earnings were 908.00 million, an increase of 30.46%.
Financial StatementsNews
Hikal successfully clears ANVISA GMP audit for Bengaluru API manufacturing facility
Hikal Ltd. has announced the successful completion of the Good Manufacturing Practices (GMP) audit conducted by the Brazilian Health Regulatory Agency (ANVISA) at its manufacturing facility located in...
Hikal receives OAI classification from US FDA for Jigani facility
Hikal Limited has announced that the United States Food and Drug Administration (US FDA) has classified its recent inspection of the company’s manufacturing facility in Jigani, Bengaluru as “Official ...
Hikal share price jumps 4% as Q4 revenue rises 7.4% YoY to Rs 552 crore, net profit up 48% YoY
Hikal Limited shares jumped 4% after the company reported a strong set of numbers for Q4 FY25. As of 3:17 PM, the shares were trading 3.51% higher at Rs 421.90. Net profit surged 48% year-on-year to ₹...
Hikal Q4 Results: Revenue up 7.4% YoY to Rs 552 crore, Net Profit up 48% YoY
Hikal Limited reported a robust performance for the fourth quarter ended March 31, 2025, with net profit rising 48% year-on-year to ₹50.2 crore, compared to ₹33.9 crore in Q4 FY24. The company’s stron...
Hikal shares drop over 6% after US FDA issues six observations for Jigani facility
Hikal Ltd’s stock tumbled over 6% in early trade after the company announced it received six observations from the US Food and Drug Administration (US FDA) for its Jigani facility in Bengaluru, Karnat...
Hikal receives 6 observations for Jigani facility from US FDA
Hikal Ltd has successfully completed a US Food and Drug Administration (US FDA) inspection at its Jigani facility in Bengaluru, Karnataka. The inspection, conducted from February 3 to February 7, 2025...